Necrostatin-7

CAS No. 351062-08-3

Necrostatin-7( —— )

Catalog No. M34110 CAS No. 351062-08-3

Necrostatin-7 (Necrostatin 7) is an inhibitor of necrotic apoptosis with cardioprotective effects, inhibits RANK-NFATc1 signaling, and attenuates macrophage differentiation into osteoblasts.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 29 In Stock
5MG 48 In Stock
10MG 83 In Stock
25MG 167 In Stock
50MG 267 In Stock
100MG 429 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Necrostatin-7
  • Note
    Research use only, not for human use.
  • Brief Description
    Necrostatin-7 (Necrostatin 7) is an inhibitor of necrotic apoptosis with cardioprotective effects, inhibits RANK-NFATc1 signaling, and attenuates macrophage differentiation into osteoblasts.
  • Description
    Necrotatin-7 (Nec-7) is a potent necroptosis inhibitor with an EC50 of 10.6 μM. Necrotatin-7 does not inhibit recombinant RIP1 kinase.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    Apoptosis
  • Recptor
    Apoptosis
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    351062-08-3
  • Formula Weight
    371.41
  • Molecular Formula
    C16H10FN5OS2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C1C(SC(=N)N1C2=NC=CS2)=CC3=CNN=C3C=4C=CC(F)=CC4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Weihong Zheng, et al. Structure-activity relationship study of a novel necroptosis inhibitor, necrostatin-7. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4932-5.?
molnova catalog
related products
  • L-Cystathionine

    L-Cystathionine is a key nonprotein amino acid related to metabolic conditions of sulfur-containing amino acids.

  • Lonicerin

    Lonicerin has antioxidant, anti-arthritic and antifungal activities, it can result in a combination therapy for the treatment of fungal arthritis due to C. albicans infection.

  • Rigosertib

    Rigosertib is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM).